| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $71,291,040 ) (Continued on the next page) |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK138998 | Characterization of microvasculature in kidney transplant by super-resolution ultrasound imaging | 000 | 2 | NIH | 4/14/2025 | $538,923 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA285345 | Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancer | 000 | 2 | NIH | 3/18/2025 | $442,842 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R33NS122096 | Intracranial D-2-Hydroxyglutarate as a Monitoring Biomarker for IDH-mutant Glioma. | 000 | 4 | NIH | 4/1/2025 | $358,007 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG1CA232760 | NCI, National Clinical Trials Network Lead Academic Participating Site (LAPS) UG1 (funded extension) | 001 | 6 | NIH | 3/18/2025 | $590,417 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG050603 | Molecular and structural imaging in atypical Alzheimer's disease: a longitudinal study | 000 | 10 | NIH | 3/18/2025 | $714,049 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG069052 | "What is N?" Towards operationalizing neurodegeneration in Alzheimer's and related dementias | 000 | 3 | NIH | 3/18/2025 | $668,066 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB031790 | Super Resolution for Improved Multislice Prostate MRI | 000 | 4 | NIH | 3/17/2025 | $560,204 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA261854 | NAD+ metabolism in PARP inhibitor resistance of ovarian cancer | 000 | 5 | NIH | 3/25/2025 | $382,174 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | P01AG062413 | Targeting Cellular Senescence to Extend Healthspan | 000 | 7 | NIH | 3/12/2025 | $3,168,053 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA262613 | Intravenous VSV virotherapy in lymphoma | 000 | 3 | NIH | 4/1/2025 | $557,778 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21EB034346 | Next generation of delivery platform for Prime editors based on an RNA vector for Sickle cell disease: the “all-in-one” vector | 000 | 2 | NIH | 4/2/2025 | $181,575 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275074 | Evaluation of novel tomosynthesis density measures in breast cancer risk prediction | 000 | 3 | NIH | 3/19/2025 | $604,359 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 001 | 1 | NIH | 4/3/2025 | -$726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 001 | 1 | NIH | 4/3/2025 | $726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA246568 | Utility of memantine in preventing cognitive dysfunction in children receiving cranial radiotherapy | 000 | 6 | NIH | 3/28/2025 | $287,216 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL084155 | Human Cardiorenal Syndrome | 000 | 13 | NIH | 3/28/2025 | $397,102 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DC014942 | The neurobiology of two distinct subtypes of neurodegenerative apraxia of speech: phenotypes of Alzheimer disease related 4-repeat tauopathies | 000 | 8 | NIH | 3/19/2025 | $579,047 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA286864 | Mechanism and therapeutic targeting of abnormal androgenesis in CHD1-deficient prostate cancer | 000 | 2 | NIH | 4/2/2025 | $406,963 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS122174 | Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy | 000 | 3 | NIH | 4/3/2025 | $587,768 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG081584 | Biophysically inspired mechanical biomarkers of normal pressure hydrocephalus | 000 | 2 | NIH | 3/20/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG086085 | Characterization of senescent cell populations in skeletal aging | 000 | 2 | NIH | 4/2/2025 | $468,748 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA283539 | RNA methylation as a novel effector of SETD2 in kidney cancer | 000 | 2 | NIH | 3/20/2025 | $169,773 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R37CA266344 | Towards Safer and More Effective CART Cell Therapy Through the Modulation of Myeloid Cytokines | 001 | 4 | NIH | 2/12/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31AI188916 | Sensitizing solid tumors to perforin-independent CAR T-cell killing | 001 | 1 | NIH | 1/8/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA275870 | Investigating the role of MAP2 in chemotherapy-induced peripheral neurotoxicity | 001 | 3 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB036987 | AI-assisted quantitative photon-counting-detector CT imaging for cytogenetic risk prediction and treatment response in multiple myeloma | 000 | 1 | NIH | 3/19/2025 | $546,874 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS112153 | Flortaucipir PET and histopathology in frontotemporal lobar degeneration and Alzheimer’s disease | 000 | 3 | NIH | 2/13/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 001 | 12 | NIH | 2/13/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI170535 | Characterizing the role of CSDE1 as a critical co-factor for VSV replication. | 000 | 3 | NIH | 2/12/2025 | $391,395 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD016230 | Rural Patient Risks and Exposures for Diabetes ConTrol (Rural PREDICT) | 000 | 5 | NIH | 2/18/2025 | $146,896 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL172948 | Understanding and addressing the lack of and delayed screening for primary Aldosteronism | 000 | 1 | NIH | 2/24/2025 | $726,611 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R13AG094182 | 6th Annual MAC (Midwest Aging Consortium) Aging Research Symposium | 000 | 1 | NIH | 4/11/2025 | $25,000 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA214679 | Multi-cancer Early Detection | 000 | 8 | NIH | 4/4/2025 | $445,446 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL167796 | Targeting Senescence Specific Mechanisms of NF-κB Activation to Reverse Chronic Pulmonary Fibrosis | 000 | 2 | NIH | 3/5/2025 | $530,118 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG076469 | A novel cilium-to-nucleus axis promotes cellular senescence | 000 | 4 | NIH | 3/6/2025 | $293,355 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK126206 | The effect of endogenous GLP-1 secretion on islet function in vivo | 000 | 6 | NIH | 3/5/2025 | $648,316 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG087140 | Neuroinflammation, white matter integrity, AD biomarkers and pathology in corticobasal syndrome | 000 | 1 | NIH | 3/27/2025 | $798,032 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AR077538 | The impact of age-related changes in osteoclast function on the skeleton | 000 | 5 | NIH | 4/16/2025 | $256,399 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA286349 | Characterization and treatment of a novel model of radiation optic neuropathy using the tree shrew | 000 | 2 | NIH | 4/4/2025 | $48,601 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA248288 | Relating Molecular Subgroups of Endometriosis-Associated Ovarian Cancers to Survival and Risk | 000 | 5 | NIH | 4/4/2025 | $272,346 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | T32DK007198 | Multidisciplinary Training in Digestive Diseases | 002 | 50 | NIH | 2/14/2025 | $187,498 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA249116 | ERβ repurposes EZH2 to suppress oncogenic NFκB signaling in TNBC | 001 | 5 | NIH | 2/14/2025 | $0 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG082681 | Role of p21 positive senescent cells in radiation-induced skeletal injury and repair | 000 | 3 | NIH | 4/9/2025 | $363,150 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL145268 | Measuring arterial material properties using wave-based approaches with ultrasound and computational models | 000 | 7 | NIH | 2/26/2025 | $616,578 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166238 | Electrochemical Catheter for Prevention of Central Line-Associated Bloodstream Infection | 000 | 3 | NIH | 2/19/2025 | $382,186 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31CA287495 | DUSP2 in Negative Regulation of Cytotoxic T Cell Responses to Immunotherapy | 001 | 2 | NIH | 4/10/2025 | $48,974 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK137231 | Engineering microcapsules for scalable differentiation of human pluripotent stem cells into hepatocytes | 000 | 2 | NIH | 2/20/2025 | $500,141 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK132718 | Noninvasive assessment of portal hypertension and hepatic interstitial pressure with advanced magnetic resonance elastography | 000 | 3 | NIH | 2/27/2025 | $310,878 |
| | 2025 | 2025 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG082708 | Investigating the role of cytosolic mitochondrial double-stranded RNA in cellular senescence and aging | 000 | 3 | NIH | 4/18/2025 | $524,959 |
|
